NCT00036127
Completed
Phase 2
Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders
ConditionsSchizophrenia
Drugsaripiprazole
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Schizophrenia
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Locations
- 2
- Status
- Completed
- Last Updated
- 12 years ago
Overview
Brief Summary
Study to learn if the alternate formulation is effective in agitated schizophrenic patients
Investigators
Eligibility Criteria
Inclusion Criteria
- •Agitated schizophrenic patients
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Study Sites (2)
Loading locations...
Similar Trials
Completed
Phase 4
Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social AnxietySchizophreniaSchizoaffective DisorderSocial Anxiety DisorderNCT00177008University of Medicine and Dentistry of New Jersey18
Completed
Not Applicable
Aripiprazole research over schizophrenia patients (both on first episode and recurrence) about its efficacy and influence on cognitive functioschizophreniaJPRN-UMIN000002076Kyoto University Hospital20
Completed
Phase 4
Aripiprazole as an Adjunct to Atypical Antipsychotics for Weight Reduction and Improvement in Metabolic ProfileAntipsychotics Weight GainNCT02949752Institute of Mental Health, Singapore67
Completed
Phase 3
Aripiprazole Oral Acceptability TrialSchizophreniaNCT00101569Otsuka Pharmaceutical Development & Commercialization, Inc.59
Completed
Not Applicable
Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar DisorderSchizophreniaBipolar DisorderNCT00216723Korea Otsuka Pharmaceutical Co., Ltd.3,000